Spark Therapeutics Stock
Your prediction
Pros and Cons of Spark Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Spark Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Spark Therapeutics | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | -1.540% | -5.970% | -8.029% | 115.385% | 51.807% | 309.756% | 147.180% |
| United Therapeutics | -0.720% | -0.801% | -3.900% | 78.050% | 7.255% | 105.978% | 195.677% |
| Ionis Pharmaceuticals Inc. | -1.480% | -0.275% | -33.163% | 32.920% | -30.547% | 30.748% | 52.850% |
News
London Stock Exchange Group H1 Earnings Call Highlights
Key Points
- Interested in London Stock Exchange Group plc? Here are five stocks we like better.
- LSEG delivered strong first-half results: Organic revenue grew 8.4%, adjusted EBITDA rose 14%
Palantir's Wild Ride: Inside the Stock Wall Street Can't Agree On
Key Points
- Interested in Palantir Technologies Inc.? Here are five stocks we like better.
- Palantir Technologies continues to post exceptional revenue growth, led by U.S. government and commercial
Dollar Tree’s Turnaround Is Starting to Take Root
Key Points
- Interested in Dollar Tree, Inc.? Here are five stocks we like better.
- Dollar Tree's board approved a $2.5 billion share repurchase in July 2026, arriving shortly after activist